Q4 2024 Collplant Biotechnologies Ltd Earnings Call Transcript
Key Points
- CollPlant Biotechnologies Ltd (CLGN) is advancing its proprietary photocurable dermal filler, which is in the preclinical phase and targets a market valued at approximately $6.3 billion with a 10% compound annual growth rate.
- The company has received positive feedback from thought leaders in aesthetic medicine regarding its photocurable dermal filler, suggesting it could be a game changer for facial plastic surgery.
- CollPlant's collaboration with AbbVie is progressing, with AbbVie collecting data from clinical trials and a recent $2 million payment received by CollPlant following a development achievement.
- The regenerative breast implant program is showing promising preclinical results, with successful tissue integration and vascularization observed in one study arm.
- CollPlant's recombinant human collagen technology is in demand, with ongoing discussions with various companies interested in accessing this technology.
- CollPlant Biotechnologies Ltd (CLGN) reported a significant decrease in GAAP revenues for 2024, with $515,000 compared to $11 million in 2023, primarily due to a $10 million milestone payment from AbbVie in 2023.
- The company experienced a GAAP gross loss of $1.1 million for the year ended December 31, 2024, compared to a gross profit of $9 million in 2023.
- GAAP net loss for 2024 was $16.6 million, significantly higher than the $7 million net loss in 2023, attributed to the absence of a large milestone payment received in the previous year.
- Cash used in operating activities increased to $14.1 million in 2024 from $2.8 million in 2023, indicating higher operational expenses.
- The company's cash runway is expected to last only until the second quarter of 2026, raising concerns about long-term financial sustainability without additional revenue streams or partnerships.
Welcome to the CollPlant Biotechnologies investor conference call to discuss financial results for the full year and fourth quarter of 2024 and corporate updates. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the call over to Dory Kurowski of Lifesci Advisors. Thank you. Please go ahead.
I would like to welcome everyone to CollPlant Biotechnologies financial results conference call to discuss the results for the full year and fourth quarter ended December 31, 2024, where management will also provide a corporate business update.
With us on the call today from CollPlant are Yehiel Tal, Chief Executive Officer, who will provide a brief overview of the company's programs and associated updates; and Eran Rotem, Deputy CEO and Chief Financial Officer, who will provide a summary of CollPlant's financial results for the full year and fourth quarter ended December 31, 2024. Both will be available to answer questions
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
